Heart Disease Prevention Program, Division of Cardiology, C240 Medical Sciences, University of California, Irvine, CA, 92697, USA.
Curr Atheroscler Rep. 2022 Dec;24(12):949-957. doi: 10.1007/s11883-022-01073-z. Epub 2022 Nov 14.
Coronary artery calcium (CAC) is an important measure of subclinical atherosclerosis and strongly predicts atherosclerotic cardiovascular disease (ASCVD) outcomes. The purpose of this review is to discuss the key studies that have helped to establish its role as an important screening tool and its place in preventive cardiology.
Epidemiologic studies document a strong relation of age, race/ethnicity, and risk factors with the prevalence and extent of CAC. Large-scale registry and prospective investigations show CAC to be the strongest subclinical disease predictor of ASCVD outcomes, with higher CAC scores associated with successively higher risks and those with a CAC score of 0 having a long-term "warranty" against having events. Moreover, CAC is associated with greater initiation of preventive health behaviors and therapy. Current US guidelines utilize CAC to inform the treatment decision for statin therapy. Further study is underway to document whether CAC screening will ultimately improve clinical outcomes. CAC is well established as the most important subclinical cardiovascular disease measure for prediction of future ASCVD outcomes and can be used for informing the treatment decision for preventive therapies.
冠状动脉钙(CAC)是亚临床动脉粥样硬化的重要指标,强烈预测动脉粥样硬化性心血管疾病(ASCVD)的结局。本文的目的是讨论有助于确立其作为重要筛查工具的作用及其在预防心脏病学中的地位的关键研究。
流行病学研究记录了年龄、种族/民族和危险因素与 CAC 的患病率和严重程度的强烈关系。大规模登记和前瞻性研究表明,CAC 是 ASCVD 结局最强的亚临床疾病预测指标,CAC 评分越高,风险越高,CAC 评分为 0 的患者长期“保证”不会发生事件。此外,CAC 与更积极地采取预防健康行为和治疗相关。目前,美国指南利用 CAC 来为他汀类药物治疗的治疗决策提供信息。正在进行进一步的研究,以证明 CAC 筛查是否最终会改善临床结局。CAC 已被确立为预测未来 ASCVD 结局的最重要的亚临床心血管疾病指标,可用于为预防治疗的治疗决策提供信息。